- Pfizer plans to close a production facility in Boulder, Colorado by 2019. First reported by the Daily Camera, the move will affect around 100 jobs.
- The 50,000 square-foot site was acquired as part of Pfizer’s acquisition of Hospira last year.
- A Pfizer spokeswoman said the company was considering options for the facility, which may include a sale.
Pfizer appears to be reshuffling its manufacturing network as it continues integration of Hospira. Although Pfizer said it would exit the site by 2019, it is not yet certain whether the company will close the plant entirely or seek a sale.
“At this point, we’re evaluating our options for the Boulder plant, which may include facilitating the sale of the site, which is currently leased,” said a Pfizer spokesperson.
Around 100 people are currently employed at the site.
Pfizer is closing the plant as it expands operations in Massachusetts. Last week the company said it would invest $200 million in a new clinical manufacturing plant in Andover, MA, which will eventually produce complex biologics and vaccines.
Daily Camera: Pfizer to close Boulder facility
FiercePharma: Pfizer closing Hospira plant in Colorado, 100 jobs to be lost
By Ned Pagliarulo | June 23, 2016